
Taiho’s DMD therapy misses the mark in Phase III trial
Taiho Pharmaceutical’s investigational Duchenne muscular dystrophy (DMD) therapy, pizuglanstat, has shown no benefit in a Phase III trial. The REACH-DMD study (NCT04587908) showed no significant difference in the mean change in time to rise from the floor …